Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid - Wikidata - awgldk - TriplyDB

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

http://www.wikidata.org/entity/Q34078408

about

Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid β levels in humans Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.The Gothenburg MCI study: Design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values Diurnal oscillation of CSF Aβ and other AD biomarkers.Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Biomarkers in frontotemporal lobar degenerations--progress and challenges.β-amyloid in biological samples: not all Aβ detection methods are created equal.Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly.Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection.A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles.Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study.CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?Amyloid-β efflux from the central nervous system into the plasma.Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.A consensus in Korea regarding a protocol to reduce preanalytical sources of variability in the measurement of the cerebrospinal fluid biomarkers of Alzheimer's disease.Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues.Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer's disease, mild cognitive impairment, or healthy controls: a two year follow-up study.The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation.Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?CSF biomarker variability in the Alzheimer's Association quality control program.The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study.No diurnal variation of classical and candidate biomarkers of Alzheimer's disease in CSF.Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ40 and Aβ42 Peptides in Plasma.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.Potential sources of interference on Abeta immunoassays in biological samples

P2860

Q24289443-F1472546-81DC-4275-ACCD-48EF0C176F47 Q26781562-1AC64E75-B8E2-42B5-BBCB-C930B2DB4AC9 Q26784569-C4465E42-87A4-460F-A6F5-5A7EA44D0733 Q26801663-6BB55495-0C51-406E-9327-530579406BAF Q27345258-D513F091-CFD0-4698-AF50-2958C8C06A72 Q28540483-B12CC05B-27AA-40C0-BDEA-2390A6CBB348 Q28741472-7307C4BA-2A4F-4B06-BE46-2509C4EB0803 Q30651551-6396D909-6BE8-439D-9433-8428F789A302 Q30980369-0067EEC9-E59D-484D-AAAC-48F35580C5AA Q31120924-198E93DD-E8DF-47E6-9080-1B579EDF8F41 Q33599653-072F3BCC-3899-456C-92A1-A16E1829E2CE Q33647053-E2425DF1-8D10-4F0C-9BE3-2B2BC8A1A7DA Q33666297-745E6FB1-E3C7-4824-B57B-DC2204E103BC Q33893515-D7F05F4B-AB18-4829-92F6-CC8B6E0FCCE9 Q34038476-87D0B67A-ECD0-4C6D-A154-BB70715BD4C5 Q34200691-90B52581-85B1-4567-902C-97F55A1CD4D4 Q34537999-C4E8467A-A202-4648-AE4D-22DB1F327BED Q34630534-9413A694-9F0E-491C-8A71-A34989FD928D Q35029099-67FD0E09-86CA-48F0-90BB-2DAB5FD67C34 Q35115904-1B462125-2338-4893-9FB3-0A4D2C4ACAE7 Q35166482-D00AC050-5030-48AE-8E66-4A12507A71B9 Q35218413-96BC5756-7A62-4DF5-837B-BA58B8398DF7 Q35291150-17248119-4D23-4FF2-B8AA-EE250EFEAFA6 Q35456060-E92ED74C-7DAE-4F6E-9F01-EFF452CF87B9 Q36062391-DE3A08E6-081E-4C76-B314-0614183F743E Q36139579-9C34B788-A67A-4E8A-84E9-800386D60818 Q36162523-43AA6E57-5653-4C2B-9764-84D7C73616FA Q36337525-3375276E-EDF7-401C-9C60-D9CC23D39C00 Q36356545-8EF2F679-B7DB-4540-B441-CFD45F506878 Q36929543-F0650DD9-5B67-424E-9178-88D9578AF637 Q36999855-F8F8368E-78BF-441D-8063-81D50EDF07A5 Q37008887-43DAA920-5E0B-47C0-81A7-05C90EC3847F Q37169132-733EE611-AD0C-4991-A2B7-AE2664649445 Q37198556-FB6F47A5-5061-4FE1-890C-AF9010EC942C Q37237233-E77A4294-0968-45A6-AEC6-6CC79874A0F7 Q37300264-3B720D61-EF93-42F9-A4D1-3FEA509AD9CB Q37494873-27E193DE-FCE2-4236-B01B-F7DE92EF1D07 Q37652424-5D678061-DAAA-406A-A59D-0FC567803716 Q38037155-E293F2F8-2D25-44C8-A042-84B53C651103 Q38053449-482036F2-B16E-45F1-9D8E-86B0B8FD696D

P2860

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

http://www.wikidata.org/entity/Q34078408

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@ast

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@en

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@nl

type

label

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@ast

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@en

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@nl

prefLabel

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@ast

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@en

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@nl

P1433

Q34078408-61C866D6-4625-4383-A79E-A6218AD94CD7

P1476

Q34078408-D564D62B-EDE4-4087-BE36-FB7B7C61E7F8

P2093

Q34078408-17CCEE6D-C1C1-43AB-8ECA-7F804416E2B7

Q34078408-4B6BD6E8-3EB7-4274-8C07-9DA8EE08036B

Q34078408-62E04C96-7214-461B-B6C3-53E5DA6C3CB7

Q34078408-7E48AE48-F701-4605-8121-BA1877CE5093

Q34078408-DD6261C7-23F5-45C5-B0E0-C653E4B837CF

P2860

Q34078408-06E696B7-8700-49F1-A146-70AAC399D57E

Q34078408-09A15293-51AA-4489-BD2B-BFD3B486EC0C

Q34078408-13B07B5F-6C03-431C-A1DC-2601BB1E1BC6

Q34078408-1637FD98-7E53-41AD-AB83-08800D3157B8

Q34078408-1A202697-D82F-49BB-B521-56317731D7EA

Q34078408-1B460A9A-EEDD-438B-BD20-8321D2FC17DC

Q34078408-1B7806F6-A35E-4833-8A5E-747988FD7D08

Q34078408-1C4DE3BC-54F8-4B00-B4FF-46B2F1DC2B58

Q34078408-2AC84795-2AAB-45FD-B465-6FECD5A62EF7

Q34078408-2CDB4589-C156-4B4F-96FD-3DF8BDB17D3B

P304

Q34078408-FF8720D1-E04B-4613-B387-0A30E4407B9A

P31

Q34078408-6EB9A7B1-502E-4926-977F-E9702AAA5B2B

P356

Q34078408-B0F59490-529B-4A15-9FD3-7FE5063FE349

P478

Q34078408-2508ED3C-1609-4D60-8AE5-1031CA5AF246

P50

Q34078408-3AC9EBD1-D514-472A-8492-D4E081882470

Q34078408-3B88E533-3D78-4A02-81E2-85CCCEC6FED0

Q34078408-71C5CDED-0376-4776-A972-90B29AF3B7EC

Q34078408-D3622CF5-E16D-4683-B9FF-38F8F960DE0E

Q34078408-F009CC7A-7C25-4FD1-8369-BFC971CC4E8E

P577

Q34078408-2EF65430-6085-4198-A527-400ED12D52E2

P5875

Q34078408-6918DCB6-6914-4E99-8C3A-731EB75635E9

P698

Q34078408-56381B09-BCB9-441F-8E0B-C6AE05FC01D4

P921

Q34078408-275E65D2-29D5-4DC6-8B43-A3F0AD352A07

P932

Q34078408-CBCECCBC-30B7-46B6-9740-9407618A295E

P356

P1433

International journal of Alzheimer's disease

P1476

Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid

@en

P2093

Anders Wallin

http://www.w3.org/2001/XMLSchema#string

Maria Bjerke

http://www.w3.org/2001/XMLSchema#string

Niels Andreasen

http://www.w3.org/2001/XMLSchema#string

Rolf Anckarsäter

http://www.w3.org/2001/XMLSchema#string

Ulf Andreasson

http://www.w3.org/2001/XMLSchema#string

P2860

Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease

Clearance of amyloid-beta by circulating lipoprotein receptors

Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

Alzheimer's disease

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

The impact of blood contamination on the proteome of cerebrospinal fluid.

Truncated cystatin C in cerebrospiral fluid: Technical [corrected] artefact or biological process?

P304

621-626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4061/2010/986310

http://www.w3.org/2001/XMLSchema#string

P478

2010

http://www.w3.org/2001/XMLSchema#string

P50

Henrik Anckarsäter

Henrik Zetterberg

Lennart Minthon

P577

2010-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46010075

http://www.w3.org/2001/XMLSchema#string

P698

20798852

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid

P932

2925386

http://www.w3.org/2001/XMLSchema#string